Related Experiment Video
Updated: Jul 1, 2026
12:48
PLGA Nanoparticles Formed by Single- or Double-emulsion with Vitamin E-TPGS
Published on: December 27, 2013
MBG/PLGA composite microspheres with prolonged drug release.
Xia Li1, Xiupeng Wang, Lingxia Zhang
1State Key Laboratory of High Performance Ceramics and Superfine Microstructure, Shanghai Institute of Ceramics, Chinese Academy of Sciences, Shanghai, People's Republic of China.
Journal of Biomedical Materials Research. Part B, Applied Biomaterials
|September 9, 2008
Summary
Mesoporous bioactive glass/poly(D,L-lactide-co-glycolide) composite microspheres offer sustained gentamicin release for over 4 weeks. This makes them promising for bone repair applications, combining antibiotic delivery with bone regeneration properties.
Area of Science:
- Biomaterials Science
- Drug Delivery Systems
- Regenerative Medicine
Background:
- Mesoporous bioactive glasses (MBG) are investigated for drug delivery.
- Biodegradable polymers like poly(D,L-lactide-co-glycolide) (PLGA) are used in biomedical applications.
- Gentamicin (GS) is a common antibiotic for bone infections.
Purpose of the Study:
- To prepare and characterize MBG and MBG/PLGA composite microspheres for gentamicin loading.
- To evaluate the in vitro drug release kinetics of gentamicin from these microspheres.
- To assess the potential of MBG/PLGA composites as drug delivery systems for bone repair.
Main Methods:
- Preparation of MBG and MBG/PLGA composite microspheres.
- Loading of gentamicin (GS) into the microspheres.
- In vitro drug release studies in distilled water and phosphate-buffered saline (PBS) at 37°C for over 30 days.
Main Results:
- MBG microspheres exhibited rapid GS release: ~60% in 24h and >80% in 2 days.
- MBG/PLGA composite microspheres showed an initial release of ~33% in 1 day and ~48% in 2 days.
- Composite microspheres demonstrated sustained GS release for over 4 weeks in PBS.
Conclusions:
- MBG/PLGA composite microspheres provide sustained antibiotic release, unlike pure MBG.
- These composites are potential candidates for bone void fillers, offering combined antibiotic delivery and osteoconductive properties.
- The sustained release profile is advantageous for preventing bone infections and promoting bone healing.
Related Concept Videos
01:05Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
01:26Oral Drug Delivery Systems: Continuous-Release Systems
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
01:19Modified-Release Drug Delivery Systems: Rate-Programmed II
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
01:11Oral Drug Delivery Systems: Delayed-Release Systems
Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...
01:22Modified-Release Drug Delivery Systems: Rate-Programmed I
Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...